Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy

Background: Despite its toxicity, modified FOLFIRINOX is the main chemotherapy for localized, operable pancreatic adenocarcinomas. Sarcopenia is known as a factor in lower overall survival (OS). The purpose of this study was to assess the impact of sarcopenia on OS in patients with localized pancrea...

Full description

Bibliographic Details
Main Authors: Victor Mortier, Felix Wei, Anna Pellat, Ugo Marchese, Anthony Dohan, Catherine Brezault, Maxime Barat, David Fuks, Philippe Soyer, Romain Coriat
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Cancers
Subjects:
pancreatic adenocarcinoma
adjuvant chemotherapy
FOLFIRINOX
gemcitabine
sarcopenia
Online Access:https://www.mdpi.com/2072-6694/14/24/6179

Internet

https://www.mdpi.com/2072-6694/14/24/6179

Similar Items